Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients

Table 1 Patients’ characteristics according to VS classification

	All patients (%)	VS-G (%)	VS-P (%)	P^a
Age (years)				0.682
Median (range)	58 (34–81)	58 (34–81)	58 (46–74)	0.682
Gender				1.000
Female	24 (33.3)	20 (33.3)	4 (33.3)
Male	48 (66.7)	40 (66.7)	8 (66.7)
ECOG PS				1.000
0	42 (58.3)	35 (58.3)	7 (58.3)
1	30 (41.7)	25 (41.7)	5 (41.7)
Stage				1.000
IIIB	14 (19.4)	12 (20.0)	2 (16.7)
IV	58 (80.6)	48 (80.0)	10 (83.3)
Smoking				0.595
Yes	41 (56.9)	35 (58.3)	6 (50.0)
No	31 (43.1)	25 (41.7)	6 (50.0)
Treatment				0.916
Chemotherapy	35 (48.6)	29 (48.3)	6 (50.0)
Chemotherapy + Bev	37 (51.4)	31 (51.7)	6 (50.0)

ECOG Eastern Cooperative Oncology Group, PS performance status, Bev bevacizumab. ^aTwo groups were compared using T test for age or using X² test for all other characteristics

ISSN: 1475-2867